
White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report
The White House has withdrawn Dr. Heidi Overton’s nomination for FDA commissioner just a day before a Senate committee vote.
The White House has pulled its
The decision comes the night before a Senate committee was due to vote on whether to advance her nomination.
A vote that never happened
Sen. Bill Cassidy, the committee’s chair, maintained Tuesday night that Dr. Overton was on the verge of garnering enough support. In a post on X shortly after her nomination was pulled, Cassidy wrote: “Tonight, the White House abandoned a viable confirmation path for Dr. Overton.” He says the withdrawal was odd given that he had been having productive conversations with members, and that he believed she would have had the votes to pass out of committee and pass the full Senate. “I believe she would have had the votes to pass out of committee and pass the full Senate. My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk,” wrote Cassidy.
Cassidy says pro-life senators sought final assurances from the administration regarding its commitment to life issues, and that the administration withdrew Overton rather than make such commitments.2
Pressure from both flanks
The withdrawal caps weeks of intensifying scrutiny over Overton’s ability from both Republican senators and activists aligned with Health and Human Services Secretary Robert F. Kennedy Jr. Trump officials spent recent days working to fend off threats to sink her nomination from Sen. Josh Hawley and the broader anti-abortion movement, who were angered by the administration’s lack of urgency in restricting distribution of mifepristone, according to two people familiar with the matter.1
Her nomination exposed fault lines between the “Make America Healthy Again” (MAHA) movement led by Kennedy and more traditional conservative circles. As a senior White House domestic policy aide, Overton spent the past year and a half as the main conduit between HHS leaders pushing key MAHA policies and top White House officials who have stalled them in recent months, sowing frustration and distrust within the broader MAHA movement.
Though Kennedy praised her nomination in August, people familiar with the dynamic between them described the relationship as strained, with one person calling their interactions icy and another saying plainly that she is not MAHA.1
An agency without a leader
Overton is the latest health care nominee pulled amid eroding GOP support; the White House has also withdrawn its picks to lead the Centers for Disease Control and Prevention and the surgeon general’s office as moderate Republicans raised concerns. The move leaves FDA without a permanent leader well into next year.
The White House has not said when, or whom, it might nominate next. Outgoing Kansas Sen. Roger Marshall, who lost his reelection bid this month, has expressed interest in the role to the administration, according to one person familiar with the discussions, though it remains unclear whether Trump would choose him or whether he could win over enough Senate colleagues given his record of aligning with the administration’s more combative MAHA positions.1
Sources
- White House drops Trump’s FDA pick amid senators’ opposition and ‘icy’ relationship with RFK Jr. CNN November 18, 2026,
https://edition.cnn.com/2026/11/17/politics/heidi-overton-white-house-drops-nomination-fda - U.S. Senator Bill Cassidy, M.D. X November 17, 2026,
https://x.com/SenBillCassidy/status/2122878548671168625
Related to this article







